The United Kingdom's Advanced Research and Invention Agency (Aria) has committed £54 million to an "accelerated adaptation" programme that will fund 14 biotechnology initiatives designed to hasten evolutionary responses in wild species to climate change and emerging diseases.
Projects funded under the programme include developing vaccines for ash trees threatened by disease, experimental skin treatments intended to protect newts, and research into gene-edited swallowtail butterflies, among other interventions. Aria, a tax-funded body often described as the brainchild of former political adviser Dominic Cummings, specialises in financing high-risk, high-reward science and technology efforts.
According to Aria, the programme's aim is to investigate whether biotechnological tools can be used to increase the resilience of wild populations by accelerating adaptive change. Supporters say such approaches could offer new options where conventional conservation methods struggle to keep pace with rapid environmental change, including rising temperatures, habitat shifts and the spread of pathogens.
The announcements are likely to prompt debate among conservationists, scientists and policymakers about the risks and ethics of deliberately intervening in wild genomes and ecosystems. Aria has emphasised that the projects are experimental and exploratory, funded to assess potential benefits, limitations and safety considerations rather than to immediately deploy altered organisms at scale.
Aria's funding decision follows a growing interest internationally in using genetic and biotechnological tools for conservation, from gene banking and assisted migration to more controversial genome-editing techniques. The agency's programme will provide data and case studies that could inform future regulation and public discussion about the role of biotechnology in responding to biodiversity loss and climate-driven threats.
Details about individual projects, timelines and the regulatory safeguards that will govern experimental work are expected to be published by Aria and the recipient research teams as the programmes progress. The agency says it will monitor outcomes closely and prioritise transparency and safety throughout the funded research.